# A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

> **NCT05119335** · PHASE1,PHASE2 · TERMINATED · sponsor: **NiKang Therapeutics, Inc.** · enrollment: 120 (actual)

## Conditions studied

- ccRCC
- Clear Cell Renal Cell Carcinoma
- Kidney Cancer
- Kidney Neoplasms
- Renal Cancer
- Renal Neoplasms
- Recurrent Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Advanced Renal Cell Carcinoma
- Hypoxia
- Renal Cell Carcinoma
- Hypoxia Inducible Factor (HIF)
- HIF2α Inhibitor
- Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
- Hypoxia Inducible Factor 2α (HIF-2α)
- Clear Cell

## Interventions

- **DRUG:** Oral NKT2152

## Key facts

- **NCT ID:** NCT05119335
- **Lead sponsor:** NiKang Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-26
- **Primary completion:** 2025-08-22
- **Final completion:** 2025-09-30
- **Target enrollment:** 120 (ACTUAL)
- **Why stopped:** This study was terminated as a result of Sponsor portfolio reprioritization.
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119335, "A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05119335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*